To learn more about these conditions and how Praluent helps treat them, see the “What is Praluent used for?” section below. Praluent is given as an injection under your skin. Praluent contains the ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the expanded indication for alirocumab injection for adult patients with homozygous ...
Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are ...
Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein ...
PARIS and TARRYTOWN, N.Y., Nov. 7, 2018 /PRNewswire/ -- TheNew England Journal of Medicine (NEJM) today published positive detailed results of the 18,924-patient ODYSSEY OUTCOMES trial. The trial met ...
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results